XTX Topco Ltd Invests $2.70 Million in Johnson & Johnson (NYSE:JNJ)

XTX Topco Ltd acquired a new position in Johnson & Johnson (NYSE:JNJ) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 18,486 shares of the company’s stock, valued at approximately $2,702,000.

Several other hedge funds and other institutional investors have also modified their holdings of JNJ. Richardson Financial Services Inc. lifted its position in shares of Johnson & Johnson by 21.5% in the second quarter. Richardson Financial Services Inc. now owns 497 shares of the company’s stock worth $73,000 after buying an additional 88 shares during the last quarter. WCG Wealth Advisors LLC lifted its stake in shares of Johnson & Johnson by 13.0% in the second quarter. WCG Wealth Advisors LLC now owns 12,124 shares of the company’s stock valued at $1,772,000 after buying an additional 1,395 shares during the period. AllGen Financial Advisors Inc. raised its stake in shares of Johnson & Johnson by 14.0% in the second quarter. AllGen Financial Advisors Inc. now owns 36,088 shares of the company’s stock valued at $5,275,000 after purchasing an additional 4,443 shares in the last quarter. Kendall Capital Management raised its stake in shares of Johnson & Johnson by 5.1% in the 2nd quarter. Kendall Capital Management now owns 7,543 shares of the company’s stock valued at $1,102,000 after buying an additional 365 shares in the last quarter. Finally, Miramar Capital LLC bought a new position in Johnson & Johnson during the second quarter worth about $258,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.5 %

Shares of JNJ stock opened at $166.17 on Thursday. The firm has a 50 day moving average price of $160.71 and a two-hundred day moving average price of $154.09. The company has a market capitalization of $399.92 billion, a PE ratio of 10.36, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.80 earnings per share. As a group, analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 2.98%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s payout ratio is 30.92%.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on JNJ shares. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. TD Cowen dropped their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Royal Bank of Canada restated an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a report on Tuesday, July 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Monday. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $173.21.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.